Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Optimer Rides High After OPT-80 C. Difficile Trial Success

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Optimer Pharmaceuticals saw its share price double from around $4 to $8 after it released data from a Phase III trial showing its orally dosed first-in-class macrocyclic antibiotic was at least as good as Vancocin (ViroPharma's oral vancomycin) - and possibly better - at treating the hospital scourge Clostridium difficile.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts